THE EXACT role of pyogenic infection in the ultimate outcome of many dermatoses is becoming of increasing interest. As new effective antibiotics become available, the need for studies to determine their effectiveness as against their sensitizing capacities in local therapy is obvious. In continuing our investigations in this field, dihydrostreptomycin seemed worthy of trial.
Herein are reported the clinical results and the bacteriologic observations elicited in the course of treatment of 159 patients with dihydrostreptomycin in various bases. Also presented are the observations relative to the development of drug resistance by some of the organisms encountered. The results elicited in the patch testing of patients never exposed to this antibiotic and of those previously exposed are given.
In 1946 Peck and co-workers1 and subsequently Bartz and co-workers2 and Fried and Wintersteiner3 described independently the preparation of dihydrostreptomycin by the catalytic reduction of streptomycin.
MILLER JL, SLATKIN MH, WECHSLER HL, JOHNSON BA. DIHYDROSTREPTOMYCIN IN TOPICAL THERAPY. Arch Derm Syphilol. 1950;61(4):648–660. doi:10.1001/archderm.1950.01530110114008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: